Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO – Get Free Report) Director Eric S. Fain sold 2,000 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $5.64, for a total value of $11,280.00. Following the completion of the transaction, the director now directly owns 44,810 shares in the company, valued at approximately $252,728.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Orchestra BioMed Stock Performance
OBIO stock opened at $5.78 on Friday. Orchestra BioMed Holdings, Inc. has a 1-year low of $4.22 and a 1-year high of $11.69. The business has a 50-day moving average price of $6.86 and a 200 day moving average price of $6.22.
Orchestra BioMed (NASDAQ:OBIO – Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.04). The company had revenue of $0.78 million for the quarter, compared to analysts’ expectations of $1.04 million. Orchestra BioMed had a negative return on equity of 89.28% and a negative net margin of 2,673.26%. On average, equities analysts anticipate that Orchestra BioMed Holdings, Inc. will post -1.67 EPS for the current year.
Hedge Funds Weigh In On Orchestra BioMed
Analysts Set New Price Targets
Several research analysts recently commented on the stock. HC Wainwright assumed coverage on shares of Orchestra BioMed in a research note on Thursday, August 22nd. They issued a “buy” rating and a $14.00 price target on the stock. Chardan Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a research report on Wednesday, June 12th. Finally, B. Riley began coverage on shares of Orchestra BioMed in a research note on Thursday, July 25th. They set a “buy” rating and a $15.00 price target for the company.
Read Our Latest Report on OBIO
About Orchestra BioMed
Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
Read More
- Five stocks we like better than Orchestra BioMed
- Investing in Commodities: What Are They? How to Invest in Them
- 3 Stocks That Could See Rising Demand Based on Latest Jobs Data
- 5 discounted opportunities for dividend growth investors
- The Squeeze is on for Petco Stock, Buy it When the Dust Settles
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 3 Leveraged ETFs to Multiply Returns
Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.